Market Overview

UPDATE: JP Morgan Initiates Infinity Pharmaceuticals at Overweight on Positive Data

Related INFI
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
3 Partnerships Pushing The Pharmaceutical Sector Forward

JP Morgan initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $42.00 price target.

JP Morgan commented, "We are initiating coverage of Infinity Pharmaceuticals with an Overweight rating based on the potential of IPI-145, the company's wholly owned, possibly best-in-class oral drug candidate for the treatment of hematologic (blood) cancers, which we believe is a billion-dollar-plus opportunity. In our view, 2013 is shaping up as another event-driven year for INFI. The stock has had an impressive run, we believe based on promising early data and recent market precedent (set by PCYC in particular)."

Infinity Pharmaceuticals closed at $33.37 on Wednesday.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters